Caris Life Sciences, Inc. (CAI)
NasdaqGS · USD · Healthcare · Biotechnology
$32.46 (+1.42%) as of
Key statistics
- Market cap
- 9.17B
- P/E (TTM)
- 19.20
- Forward P/E
- 87.26
- EPS (TTM)
- 1.69
- Dividend yield
- 0.00%
- 52-week range
- 14.19 – 32.89
- Revenue (TTM)
- 989.6M
- Profit margin
- 10.62%
- Analyst target
- $32.08
- Volume
- 2.00M
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Irving, TX, United States
- Employees
- 1,846
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.